Pharmacological treatment of unipolar depressive disorders: summary of WFSBP guidelines

被引:107
|
作者
Bauer, Michael [1 ]
Severus, Emanuel [1 ]
Moller, Hans-Jurgen [2 ]
Young, Allan H. [3 ]
机构
[1] Tech Univ Dresden, Univ Hosp Carl Gustav Carus, Dept Psychiat & Psychotherapy, Fetscherstr 74, D-01307 Dresden, Germany
[2] Ludwig Maximilians Univ Munchen, Dept Psychiat, Munich, Germany
[3] Kings Coll London, Inst Psychiat Psychol & Neurosci, Dept Psychol Med, London, England
关键词
Primary care; major depressive disorder; pharmacotherapy; guidelines; CONTINUATION TREATMENT; BIOLOGICAL TREATMENT; CONTROLLED-TRIALS; MAJOR DEPRESSION; WORLD FEDERATION; DOUBLE-BLIND; ANTIDEPRESSANTS; METAANALYSIS; UPDATE; MANAGEMENT;
D O I
10.1080/13651501.2017.1306082
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Objective: Major depressive disorder (MDD) is a severe mood disorder affecting individuals of all ages and is characterised by single or recurrent major depressive episodes. Key elements of acute and maintenance treatment of MDD include pharmacotherapy, and psychological approaches such as psychoeducation and adherence monitoring.Methods: This summary of the Practice guidelines for the biological treatment of unipolar depressive disorders' comprises acute, continuation and maintenance treatment developed by an international Task Force of the World Federation of Societies of Biological Psychiatry (WFSBP), and focuses on pharmacological treatment options.Results: A variety of different antidepressants are available for the effective acute and prophylactic treatment of depressed patients. Randomised placebo-controlled efficacy studies indicate that all major classes of antidepressants are effective in acute treatment but also in preventing recurrence of depression showing about a two-fold higher relapse rate with placebo treatment. Evidence suggests that the newer' antidepressants have superior long-term effectiveness due to better tolerability and safety profile compared to traditional antidepressants, e.g., the tricyclic antidepressants (TCA).Conclusions: Despite progress in the availability of different treatment options there is still a substantial proportion of patients who do not achieve full remission. Several add-on pharmacological treatment options are among the best-evidenced strategies for refractory depressed patients.
引用
收藏
页码:166 / 176
页数:11
相关论文
共 50 条
  • [1] Updated WFSBP guidelines for the biological treatment of unipolar depressive disorders in primary care
    Bauer, Michael
    WORLD JOURNAL OF BIOLOGICAL PSYCHIATRY, 2007, 8 (02): : 66 - 66
  • [2] World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders, Part 1: Update 2013 on the acute and continuation treatment of unipolar depressive disorders
    Bauer, Michael
    Pfennig, Andrea
    Severus, Emanuel
    Whybrow, Peter C.
    Angst, Jules
    Moeller, Hans-Juergen
    WORLD JOURNAL OF BIOLOGICAL PSYCHIATRY, 2013, 14 (05): : 334 - 385
  • [3] World federation of societies of biological psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders in primary care
    Bauer, Michael
    Bschor, Tom
    Pfennig, Andrea
    Whybrow, Peter C.
    Angst, Jules
    Versiani, Marcio
    Moeller, Hans-Juergen
    WORLD JOURNAL OF BIOLOGICAL PSYCHIATRY, 2007, 8 (02): : 67 - 104
  • [4] World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for biological treatment of unipolar depressive disorders, part 2: maintenance treatment of major depressive disorder and treatment of chronic depressive disorders and subthreshold depressions
    Bauer, Michael
    Whybrow, Peter C.
    Angst, Jules
    Versiani, Marcio
    Moeller, Hans-Juergen
    REVISTA DE PSIQUIATRIA CLINICA, 2009, 36 : 58 - 76
  • [5] World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for biological treatment of unipolar depressive disorders, part 1: acute and continuation treatment of major depressive disorder
    Bauer, Michael
    Whybrow, Peter C.
    Angst, Jules
    Versiani, Marcio
    Moeller, Hans-Juergen
    REVISTA DE PSIQUIATRIA CLINICA, 2009, 36 : 17 - 57
  • [6] World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Pharmacological Treatment of Eating Disorders
    Aigner, Martin
    Treasure, Janet
    Kaye, Walter
    Kasper, Siegfried
    WORLD JOURNAL OF BIOLOGICAL PSYCHIATRY, 2011, 12 (06): : 400 - 443
  • [7] World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders. Part 2: Maintenance Treatment of Major Depressive Disorder-Update 2015
    Bauer, Michael
    Severus, Emanuel
    Koehler, Stephan
    Whybrow, Peter C.
    Angst, Jules
    Moeller, Hans-Juergen
    WORLD JOURNAL OF BIOLOGICAL PSYCHIATRY, 2015, 16 (02): : 76 - 95
  • [8] The World Federation of Societies of Biological Psychiatry (WFSBP) 2020 guidelines for the pharmacological treatment of paraphilic disorders
    Thibaut, Florence
    Cosyns, Paul
    Fedoroff, John Paul
    Briken, Peer
    Goethals, Kris
    Bradford, John M. W.
    WORLD JOURNAL OF BIOLOGICAL PSYCHIATRY, 2020, 21 (06): : 412 - 490
  • [9] World Federation of Societies of Biological Psychiatry (WFSBP) guidelines update 2023 on the pharmacological treatment of eating disorders
    Himmerich, Hubertus
    Lewis, Yael Doreen
    Conti, Chiara
    Mutwalli, Hiba
    Karwautz, Andreas
    Sjoegren, Jan Magnus
    Uribe Isaza, Maria Mercedes
    Tyszkiewicz-Nwafor, Marta
    Aigner, Martin L.
    McElroy, Susan
    Treasure, Janet
    Kasper, Siegfried
    WORLD JOURNAL OF BIOLOGICAL PSYCHIATRY, 2023, 24 (08): : 643 - 706
  • [10] WFSBP* and IAWMH** Guidelines for the treatment of alcohol use disorders in pregnant women
    Thibaut, Florence
    Chagraoui, Abdeslam
    Buckley, Leslie
    Gressier, Florence
    Labad, Javier
    Lamy, Sandrine
    Potenza, Marc N.
    Rondon, Marta
    Riecher-Rossler, Anita
    Soyka, Michael
    Yonkers, Kim
    Gorelick, David A.
    WORLD JOURNAL OF BIOLOGICAL PSYCHIATRY, 2019, 20 (01): : 17 - 50